Compliance concerns hinder rollout of AI in drug manufacturing: Survey

Summary

A CRB survey reveals that over 90% of drugmakers have not committed to scaling AI use in regulated biopharma manufacturing, citing compliance concerns as a barrier despite AI's growing adoption in administrative and drug discovery applications.